Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.

David M. Asmuth,Robert Leo Murphy,Susan L. Rosenkranz,Juan J.L. Lertora,Shyam Kottilil,Yoninah Cramer,Ellen S. Chan,Robert T. Schooley,Charles R. Rinaldo,Nathan M. Thielman,Xiao Dong Li,Sharon M. Wahl,Jessica Shore,Jennifer Janik,Richard A. Lempicki,Yaa Simpson,Richard B. Pollard

Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.

2010

David M. Asmuth
Robert Leo Murphy
Susan L. Rosenkranz
Juan J.L. Lertora
Shyam Kottilil
Yoninah Cramer
Ellen S. Chan
Robert T. Schooley
Charles R. Rinaldo
Nathan M. Thielman
Xiao Dong Li
Sharon M. Wahl
Jessica Shore
Jennifer Janik
Richard A. Lempicki
Yaa Simpson
Richard B. Pollard

Background The antiviral activity of pegylated interferon-alpha-2a has not been studied in untreated HIV-1-infected subjects without chronic hepatitis C virus (HCV) infection.

Keywords:

Hepatitis C virus
Virology
Clinical trial
Immunology
Peginterferon alfa-2a
Hepatitis C
Interferon
Medicine
Viral load
Pegylated interferon
Tolerability
Phases of clinical research
Pharmacodynamics

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

100

Citations